Effects of some convulsant agents on the protective activity of topiramate against maximal electroshock-induced seizures in mice

Pharmacological Reports

Volumn 57, Issue 3, 2005, Pages 373-379

  Świader, Mariusz J ^a   Łuszczki, Jarogniew J ^a   Zwolan, Anna ^a   Wielosz, Marian ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Bicuculline; Kainate; Maximal electroshock induced seizures; N methyl D aspartate; Topiramate

Indexed keywords

BICUCULLINE; CONVULSANT AGENT; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; TOPIRAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG BLOOD LEVEL; ELECTRIC SHOCK; IMMUNOFLUORESCENCE; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PROTECTION; SEIZURE;

EID: 22744446683     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Angehagen M, Ben Menachem E, Ronnback L, Hansson E: Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res, 2003, 54, 63-71.
2. Angehagen M, Ben Menachem E, Shank R, Ronnback L, Hansson E: Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem, 2004, 88, 320-325.
3. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res, 1999, 34, 1-41.
4. Boissier JR, Tardy J, Diverres JC: Une nouvelle methode simple pour explorer l'action' 'tranquilisante': le test de. la cheminee. Med Exp, 1960, 3, 81-84.
5. Borowicz KK, Duda AM, Kleinrok Z, Czuczwar SJ: Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats. Pol J Pharmacol, 2001, 53, 101-108.
6. Borowicz KK, Świader M, Zgrajka W, Sawulski C, Turski WA, Czuczwar SJ: Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. J Physiol Pharmacol, 2002, 53, 859-869.
7. Chapman AG, Smith SE, Meldrum BS: The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res, 1991, 9, 92-96.
8. Croucher MJ, Collins JF, Meldrum BS: Anticonvulsant action of excitatory amino acid antagonists. Science, 1982, 216, 999-901.
9. Czuczwar SJ, Ikonomidou C, Kleinrok Z, Turski L, Turski W: Effect of aminophylline on the protective action of common antiepileptic drugs against electroconvulsions in mice. Epilepsia, 1986, 27, 204-208.
10. Czuczwar SJ, Meldrum B: Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur J Pharmacol, 1982, 83, 335-338.
11. Czuczwar SJ, Turski L, Schwarz M, Turski WA, Kleinrok Z: Effects of excitatory amino-acid antagonists on the anticonvulsant action of phenobarbital or diphenylhydantoin in mice. Eur J Pharmacol, 1984, 100, 357-362.
12. Danysz W, Parsons CG, Karcz-Kubicha M, Schwaier A, Popik P, Wedzony K, Łazarewicz J et al.: GlycineB antagonists as potential therapeutic agents. Previous hopes and present reality. Amino Acids, 1998, 14, 235-239.
13. De Sarro G, Gratteri S, Bonacci F, Musumeci SA, Elia M, De Sarro A: Topiramate potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Eur J Pharmacol, 2000, 388, 163-170.
14. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM: Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology, 2002, 42, 210-220.
15. Kamiński RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology, 2004, 46, 1097-1104.
16. Kelly K, Stephen LJ, Sills GJ, Brodie MJ: Topiramate in patients with learning disability and refractory epilepsy. Epilepsia, 2002, 43, 399-402.
17. Leach JP, Brodie MJ: New antiepileptic drugs - an explosion of activity. Seizure, 1995, 4, 5-17.
18. Li X, Ketter TA, Frye MA: Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord, 2002, 69, 1-14.
19. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
20. Łuszczki JJ, Czuczwar M, Kiś J, Krysa J, Pasztelan I, Świader M, Czuczwar SJ: Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia, 2003, 44, 1003-1013.
21. Meldrum BS: Epilepsy and GABA-mediated inhibition. Int Rev Neurobiol, 1975, 17, 1-36.
22. Nakamura J, Tamura S, Kanda T, Ishii A, Ishihara K, Serikawa T, Yamada J, Sasa M: Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol, 1994, 254, 83-89.
23. Pietrasiewicz T, Czechowska G, Dziki M, Turski WA, Kleinrok Z, Czuczwar SJ: Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics. Eur J Pharmacol, 1993, 250, 1-7.
24. Pilip S, Urbańska EM, Świader M, Włodarczyk D, Kleinrok Z, Czuczwar SJ, Turski WA: Anticonvulsant action of chlormethiazole is prevented by subconvulsive amounts of strychnine and aminophylline but not by bicuculline and picrotoxin. Pol J Pharmacol, 2000, 52, 267-273.
25. Sabers A, Gram L: Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs, 2000, 60, 23-33.
26. Schneiderman JH: Topiramate: pharmacokinetics and pharmacodynamics. Can J Neurol Sci, 1998, 25, S3-S5.
27. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia, 1994, 35, 450-460.
28. Skradski S, White HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia, 2000, 41, Suppl 1, S45-S47.
29. Świader M, Gasior M, Wielosz M, Czuczwar SJ: Influence of some convulsant agents on the protective activity of a novel antiepileptic drug, felbamate, against maximal electroshock in mice. Pol J Pharmacol, 2003, 55, 649-653.
30. Świader M, Kotowski J, Gasior M, Kleinrok Z, Czuczwar SJ: Interaction of topiramate with conventional antiepileptic drugs in mice. Eur J Pharmacol, 2000, 399, 35-41.
31. Turski L, Niemann W, Stephens DN: Differential effects of antiepileptic drugs and beta-carbolines on seizures induced by excitatory amino acids. Neuroscience, 1990, 39, 799-807.
32. Urbańska EM, Tomczyk T, Haberek G, Pilip S, Matyska J, Turski WA, Kleinrok Z, Czuczwar SJ: NMDA- but not kainate-mediated events reduce efficacy of some antiepileptic drugs against generalized tonic-clonic seizures in mice. Epilepsia, 1999, 40, 1507-1511.
33. Venault P, Chapouthier P, de Carvallo LP, Simiand J, Morre M, Dodd RH, Rossier J: Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature, 1986, 321, 864-866.
34. Wauquier A, Zhou S: Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res, 1996, 24, 73-77.
35. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res, 1997, 28, 167-179.
36. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia, 2000, 41, Suppl 1, S17-S20.
37. Zhang X, Velumian AA, Jones OT, Carlen PL: Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia, 2000, 41, Suppl, S52-S60.